Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Change in Account Payables (2022 - 2024)

Historic Change in Account Payables for Indivior Pharmaceuticals (INDV) over the last 3 years, with Q4 2024 value amounting to -$24.0 million.

  • Indivior Pharmaceuticals' Change in Account Payables fell 20000.0% to -$24.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was $48.0 million, marking a year-over-year decrease of 5826.09%. This contributed to the annual value of $48.0 million for FY2024, which is 5826.09% down from last year.
  • Per Indivior Pharmaceuticals' latest filing, its Change in Account Payables stood at -$24.0 million for Q4 2024, which was down 20000.0% from $4.0 million recorded in Q3 2024.
  • Over the past 5 years, Indivior Pharmaceuticals' Change in Account Payables peaked at $55.0 million during Q2 2024, and registered a low of -$46.0 million during Q3 2022.
  • For the 3-year period, Indivior Pharmaceuticals' Change in Account Payables averaged around $9.4 million, with its median value being $18.5 million (2023).
  • Per our database at Business Quant, Indivior Pharmaceuticals' Change in Account Payables skyrocketed by 20434.78% in 2023 and then plummeted by 20000.0% in 2024.
  • Over the past 3 years, Indivior Pharmaceuticals' Change in Account Payables (Quarter) stood at -$23.0 million in 2022, then soared by 204.35% to $24.0 million in 2023, then crashed by 200.0% to -$24.0 million in 2024.
  • Its Change in Account Payables stands at -$24.0 million for Q4 2024, versus $4.0 million for Q3 2024 and $55.0 million for Q2 2024.